Investigating how statin drugs may help prevent lethal prostate cancer
Treg functional changes: a novel immune regulatory effect underlying the benefit of statin drug use on lethal prostate cancer
This study is looking at how statin medications, often used for cholesterol, might help prevent serious prostate cancer by changing how certain immune cells work, and it's for men with prostate cancer who are taking or considering taking statins.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11074087 on NIH RePORTER |
What this research studies
This research explores the potential benefits of statin drugs in preventing lethal prostate cancer by examining their effects on immune cells known as regulatory T lymphocytes (Tregs). The study aims to understand how statins may alter the tumor microenvironment and immune response, particularly focusing on a protein called YAP that influences Treg function. By comparing tissue samples from prostate cancer patients who use statins with those who do not, the researchers hope to identify key differences in immune cell behavior that could lead to improved cancer outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with localized prostate cancer who are either currently using statin medications or have not used them.
Not a fit: Patients with advanced prostate cancer who are not candidates for statin therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide insights into new therapeutic strategies for preventing the progression of lethal prostate cancer in patients using statins.
How similar studies have performed: Previous studies have shown a promising association between statin use and reduced risk of lethal prostate cancer, suggesting that this research builds on established findings.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Marrone, Michael Thomas — Medical University of South Carolina
- Study coordinator: Marrone, Michael Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.